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Vaccines have been invaluable for global health, saving lives and reducing healthcare costs,
while also raising the quality of human life. However, newly emerging infectious diseases
(EID) and more well-established tropical disease pathogens present complex challenges to
vaccine developers; in particular, neglected tropical diseases, which are most prevalent among
the world’s poorest, include many pathogens with large sizes, multistage life cycles and a
variety of nonhuman vectors. EID such as MERS-CoV and H7N9 are highly pathogenic for
humans. For many of these pathogens, while their genomes are available, immune correlates
of protection are currently unknown. These complexities make developing vaccines for EID
and neglected tropical diseases all the more difficult. In this review, we describe the
implementation of an immunoinformatics-driven approach to systematically search for key
determinants of immunity in newly available genome sequence data and design vaccines.
This approach holds promise for the development of 21st century vaccines, improving human
health everywhere.
KEYWORDS: Brugia malayi • computational vaccinology • EID • EpiMatrix • filarial • immunogenicity
• immunoinformatics • immunomics • JanusMatrix • MHC • NTD • T cell • TCR • tregitope

Neglected tropical & emerging infectious
diseases: new challenges

Climate change and international travel have
had a dramatic impact on the geographic distribution of pathogens infecting humans and
animals. Old world pathogens such as Dengue
and Chikungunya virus, previously restricted
to the Middle East, Africa and Asia have now
appeared in the Americas [1]. Newer pathogens
such as Middle East Respiratory Syndrome
coronavirus (MERS-CoV), an entirely new
coronavirus affecting humans, have been
spreading beyond the region of the world
from which they derive their names [2]. Meanwhile, human populations in developing areas
of the world continue to be threatened by
neglected tropical diseases (NTD). More than
two billion people – nearly 30% of the world’s
population – suffer from one or more
informahealthcare.com
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NTD [3], which include leishmaniasis, lymphatic filariasis, onchocerciasis, schistosomiasis
and soil-transmitted helminthiasis, among
others (TABLE 1). In addition to climate change
and airline travel, economic conditions leading
to transmigration contribute to the spread of
NTD. Recent examples include the reemergence of Leishmania in Spain [4] and Chagas
disease in Texas [5].
Even while NTD expand their reach, vaccine development for these diseases lags
behind. In contrast, vaccines for important
emerging infectious diseases (EID, TABLE 2) are
being developed, to a certain extent, by large
biotechnology companies, particularly when
these companies receive guaranteed purchase
agreements or other incentives to accelerate
vaccine development. Examples include the
development of a vaccine for H7N9 (an
emerging avian influenza) by Novartis and
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Table 1. The neglected tropical diseases.
Disease

Primary causative agents

Primary vector(s)

DALYs  1000
(95% UI)

Buruli ulcer

Mycobacterium ulcerans

Aquatic arthropods

ND

Dracunculiasis

Dracunculus medinensis

Cyclops water fleas

ND

Human African
trypanosomiasis

Trypanosoma brucei

Tsetse flies

560
(76–1766)

Leishmaniasis

Leishmania spp.

Phlebotomine sand flies

3317
(2180–4890)

Leprosy

Mycobacterium leprae, Mycobacterium
lepromatosis

–

6
(3–11)

Lymphatic filariasis

Wuchereria bancrofti,
Brugia malayi, Loa loa

Mosquitoes

2774
(1807–4000)

Schistosomiasis

Shistosoma spp.

Freshwater snails

3309
(1705–6260)

Soil-transmitted
helminthiasis

Ancylostoma duodenale, Necator
americanus, Ascaris lumbricoides,
Trichuris trichiura

Fecal-oral transmission

ND

Trachoma

Chlamydia trachomatis

Fomites, houseflies, others

5
(4–6)

Yaws

Treponema pallidum pertenue

Direct contact

ND

Chagas disease

Trypanosoma cruzi

Triatomine bugs

546
(271–1054)

Chikungunya

Chikungunya virus

Aedes mosquitoes

ND

Dengue and severe
dengue

Dengue virus

Aedes mosquitoes

825
(344–1412)

Echinococcosis

Echinococcus granulosus

Fecal-oral transmission

144
(69–286)

Foodborne
trematodiases

Clonorchis sinensis, Opisthorchis spp.,
Fasciola spp., Paragonimus spp.

Oral transmission

1875
(708–4837)

Onchocerciasis

Onchocerca volvulus

Black flies

494
(360–656)

Taeniasis/
cysticercosis

Taenia solium

Oral transmission

503
(379–663)
(cysticercosis only)

Affecting more than two billion people, the neglected tropical diseases shown here lack effective vaccines.
Computational vaccinology tools represent an accelerated, cost-sparing approach to vaccine design for these challenging targets. DALYs reflect global sum of years of
life lost and years lived with disability as of 2010, presented with 95% UI.
DALYs: Disability-adjusted life year; ND: No data; UI: Uncertainty interval.
Data taken from [96].

Novavax in 2013 [6,7] and work toward the development of a
new MERS-CoV vaccine in 2014 [8]. However, the standard
approach to develop new vaccines for emerging (and reemerging) infectious disease threats, which is to implement previously
existing vaccine design methodologies such as cloning and
expressing the dominant surface antigen [9], frequently results
in the development of vaccines that are only effective when
given with strong adjuvants [10]. This approach is particularly
unlikely to work for pathogens that have complex lifecycles
(such as parasites) or are highly mutable (such as RNA viruses).
22

This article will discuss new, computational approaches that
may accelerate and improve the design of vaccines for NTD
and EID.
Truly effective vaccines do not exist for the majority of
NTD. Although vaccines are in development for several NTD
pathogens [11], lack of financial incentive to invest in research
and development programs for diseases concentrated in lowincome countries has mired the progress of vaccine efforts
among large pharmaceutical companies [3]. Preventative chemotherapy mass drug administration (MDA) programs employing
Expert Rev. Vaccines 14(1), (2015)
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Table 2. Emerging infectious diseases (as of 2014).
Disease

Primary causative agents

Primary vector(s)

DALYs  1000
(95% UI)

Anthrax

Bacillus anthracis

Animal remains

ND

Infections caused
by microbes that
have developed
antimicrobial
resistance

Mycobacterium tuberculosis
Staphylococcus aureus
Enterococcus spp.
Neisseria spp.
Gonorrhoeae spp.

Various

ND

Botulism

Clostridium botulinum toxin

Oral transmission

ND

Campylobacteriosis

Campylobacter spp.

Fecal-oral transmission

7541
(5687–9374)

MERS, SARS

Coronaviruses

–

Dengue fever

DEN-1, DEN-2, DEN-3,
DEN-4 virus

Aedes mosquitoes

825
(344–1412)

Ehrlichiosis

Ehrlichia bacterium

Blacklegged ticks

ND

Enteropathogenic
Eschericia coli
(EPEC)
Enterotoxigenic
E. coli (ETEC)

E. coli

Fecal-oral transmission, other

EPEC: 7542
(5686–9524)
ETEC: 6894
(5619–8286)

Flu (influenza)

Avian/porcine influenza strains

Birds, pigs

19,244
(16,906–21,451)

Group A
streptococcal
infections

Streptococcus pyogenes

Direct contact, oral
transmission

ND

Hepatitis

Hepatitis A, B, C, D or E virus

Various

13,258
(11,364–15,855)

Lyme disease

Borrelia burgdorferi

Blacklegged ticks

ND

Plague

Yersinia pestis

Infected animals, rodent fleas

ND

Prion diseases

Abnormal prions

Sporadically or inherited
mutation of prion gene

ND

Salmonellosis

Salmonella spp.

Undercooked or raw meat,
reptiles

4847
(3819–5949)

Shigellosis

Shigella spp.

Fomites, houseflies, other

7052
(5676–8466)

Tularemia

Francisella tularensis

Ticks, deer flies, infected
animals

ND

West Nile virus

Flavivirus

Mosquitoes

ND

Most emerging/reemerging infectious diseases shown here lack effective vaccines.
Computational vaccinology tools represent an accelerated, cost-sparing approach to vaccine design for these challenging targets. DALYs reflect global sum of years of
life lost and years lived with disability as of 2010, presented with 95% UI.
DALYs: Disability-adjusted life year; ND: No data; UI: Uncertainty interval.
Data taken from [96].

donated or extremely low-cost generic drugs are currently in
progress to control lymphatic filariasis, onchocerciasis, leprosy,
trachoma and helminthiases in many areas of the world [12].
A complication inherent in this strategy is that because the
regions affected by different NTD overlap, coinfections can be
difficult to manage with antiparasitic agents [13]. The success of
informahealthcare.com

these long-term efforts and off-target effects of mass-eradication
campaigns at the individual and population levels remain to be
determined [14]. As has been observed for polio, geopolitical
upheaval may hamper global efforts to eradicate NTD. Thus,
effective NTD vaccines are still needed [15]. New cost–effective
design methodologies can help to bridge the gap between the
23
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great need for these vaccines and return on investment for
pharmaceutical companies.
Fortunately, genomes for many newly emerging pathogens
and neglected tropical disease-associated pathogens are becoming available due to research efforts worldwide [16]. The availability of these genomes now makes it possible to apply
computational vaccinology tools to these diseases of global
health importance.
Basic principles of vaccinology

Host immune response to pathogens is mediated by the innate
and adaptive arms of the immune system. Innate immune cells
such as macrophages, neutrophils and natural killer cells are
responsible for the first line of defense, while adaptive immunity provides a more targeted response to pathogens that establishes immune memory for more rapid responses upon
repeated exposures. B cells produce antibodies which are capable of recognizing and neutralizing pathogenic antigens. T cells
support antibody production, activation and memory development, and are capable of lysing infected cells. The potent
response from T and B cells, however, comes at a cost.
Whereas innate immune cells can respond within 24–72 h, the
primary adaptive response normally takes 7–14 days to mature.
Secondary adaptive responses driven by immune memory are
much faster and much stronger. This is the principle behind
vaccination: pre-exposure to pathogen-derived antigens can
induce pathogen-specific immune memory. The discovery of
critical antigens that drive protective memory is facilitated by
new computational tools.
Indeed, the general principle that immune cells develop
memory to specific pathogen components – has driven the
development of genome-derived vaccines over the past two decades. Since T cells play a critical role in adaptive immunity
and the development of immune memory required for an efficacious vaccine, computational tools have been used to search
for small linear peptides (T-cell epitopes) derived from protein
antigens that drive class I and class II T-cell responses. These
peptides are displayed on the surface of APC by multiple alleles
of the MHC. As human beings express multiple alleles of class
I and class II MHC molecules, called human leukocyte antigens (HLA), computational vaccinologists now search for T-cell
epitopes that can bind to the most common HLA alleles in the
human population, reasoning that broad HLA coverage will
contribute to the development of effective genome-derived vaccines. Computational tools can also be used to select epitoperich surface proteins that are better immunogens to drive B-cell
response. Fortunately, while B cells and antibodies generally
recognize surface proteins, T cells recognize epitopes derived
from a broader range of proteins, giving the computational vaccinologist many possible sources (internal and external proteins
as well as secreted proteins) for the selection of T-cell epitopes
for vaccines.
Exposure to a given pathogen generates memory T-cell
clones capable of rapid and efficient response upon subsequent reinfection [17]. This response may include T cell help
24

for induction of higher antibody titers, T-cell-mediated lysis
of infected cells and the expression of cytokines to coordinate
other cell-mediated immune processes such as activation of
APC. Breadth of T-cell response (responding to many different epitopes) appears to be correlated with protection from
severe disease for many pathogens that affect humans. More
specifically, for HIV, HBV, HCV, lymphocytic choriomeningitis virus and malaria, protection from disease has been correlated with broad T-cell epitope response to both
‘immunodominant’ and subdominant T-cell epitopes [18–22].
These discoveries have contributed to the concept that vaccines can be made directly from genomes by selecting sets of
epitopes that will stimulate immune responses and protect
against diseases.
Based on the observation that broad T-cell response may
be protective, computational vaccinologists have worked to
define collections of T-cell epitopes that can recreate the requisite features of this response. T-cell-driven, epitope-based
strategies for developing vaccines against EID and NTD are
currently the focus of several NTD research laboratories.
Proof of principle exists for a number of disease models: cellular immunity elicited by epitope immunization provided
complete protection against respiratory syncytial virus challenge, partial protection of BALB/c mice against sporozoite
challenge, elimination of malaria-infected hepatocytes
in vitro, partial protection of BALB/c and CBA against
encephalitis following intracerebral challenge with a lethal
dose of measles virus, complete protection from intraperitoneal HSV challenge, protection against infection with malaria
or influenza A virus and full protection of sheep against
bovine leukemia virus (these examples are reviewed in [23]).
We have demonstrated complete protection against lethal
vaccinia challenge [24] and successful clearance of a chronic
bacterial infection (Helicobacter pylori) following T-cell epitope-driven vaccination [25]. In earlier studies, we achieved
partial protection against an aerosolized bacterial pathogen
(Tularemia [26]) using a vaccine that contained only 14 epitopes. While mice are not humans, growing evidence that
T-cell epitope-driven vaccines can be effective in humans has
led to the establishment of a number of biotech startups and
venture-backed companies focused entirely on T-cell epitopebased vaccines.
T-cell epitopes as ‘ payload’

As described in the following sections, computational tools are
being used to identify proteins or antigens of interest directly
from the genomes of pathogens. In theory, a minimal set of
antigens or epitopes that induce a competent immune response
to a pathogen can be discovered using the new tools. Adjuvant
triggers innate immunity, which is an essential component of
the protective immune response, directing it toward inflammation rather than tolerance. When combined with the minimum
antigenic components that comprise the ‘payload’ of a genomederived vaccine, delivered in the right vehicle, may trigger protective immune response. The fundamental principle of the
Expert Rev. Vaccines 14(1), (2015)
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genome-derived epitope-driven vaccine approach is illustrated
Tthus:
Immunogenic Payload + Adjuvant + Delivery vehicle = Vaccinee

The importance of epitopes as key determinants of protective
immune responses is reflected by the flurry of immunoinformatics activity over the past decades. A number of T-cell epitope mapping tools have been developed to accelerate the
identification of these critical components of the immune
response. Using methods such as frequency analysis, support
vector machines, hidden Markov models and neural networks,
researchers have developed highly accurate tools for modeling
the MHC-peptide interface and predicting T-cell epitopes.
Available tools have been comprehensively reviewed: see
Brusic et al. [27], De Groot and Martin [28] and Sette et al. [29].
The concept was at first called ‘vaccinomics’ by Brusic and Petrovsky in 2002 [30], then ‘reverse vaccinology’ by Rappuoli in
2003 [31] and, more recently, ‘immunome-derived’ or ‘genomederived vaccine design’ by Pederson [32]; De Groot and Martin [33]; and Doytchinova, Taylor and Flower [34].
B-cell epitopes: T-cell epitope content as a proxy for B-cell
response?

Computational vaccinologists have been unable to successfully
develop accurate tools for B-cell epitope prediction, even
though one of the most commonly measured outcomes of vaccination and accepted determinant of protection is antibody
generation [35,36]. Thus, current computational vaccinology
approaches to vaccine development must take B-cell response
into consideration and develop approaches that include means
of stimulating effective humoral immunity where it is required
for protection against challenge. Given T-cell dependence for
essential features of an effective antibody response, including Bcell affinity maturation, class switch recombination, plasma cell
differentiation and memory B-cell differentiation [37], T-cell
epitope analysis and quantification have been used by our
group as a proxy for identifying good B-cell immunogens, linking in silico sequence analysis to desired putative B-cell
responses [28].
The iVAX approach to design genome-derived
epitope-driven vaccines

De Groot and colleagues have integrated epitope-mapping tools
with a wider array of vaccine design algorithms into the webbased iVAX toolkit, which will be described in some detail in
the following sections. The tools were initially used by EpiVax
and collaborators [23,38–42], and then expanded and refined for
projects that have been in progress at the Institute of Immunology and Informatics (iCubed) [43–45]. The iVAX toolkit is currently in use for NTD research at the iCubed and with
academic collaborators under an agreement established between
EpiVax and URI in 2009. iVAX tools are being used to evaluate the protective potential of existing NTD and EID vaccines [46,47], to predict immune response to newly emerging
informahealthcare.com
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pathogens [9,10] and to design novel NTD vaccines composed
of T-cell epitopes (for Chagas disease, Brugia malayi and several
different species of Leishmania [48]). In the following few sections, we describe the iVAX approach to design genomederived epitope-driven vaccines for NTD and EID.
Selecting targets

One of the first questions facing computational vaccinologists
is how to prioritize their search for antigenic proteins and epitope subunits. The entire set of proteins derived from a pathogen’s genome is an unlikely point of departure for epitope
mapping, since many of these proteins may not be part of the
‘core genome’ for a set of bacterial or viral strains of the same
pathogen. Others may be proteins that serve as ‘housekeeping’
genes that are also well conserved in harmless commensal
organisms. On the other hand, proteins that are highly conserved across variant strains, that are pathogen-specific and
those that are upregulated during interactions with the host,
particularly those that are secreted by a pathogen (presumably
in an attempt to alter the host environment), are excellent targets for vaccine development.
In addition to targeting upregulated, secreted and
pathogen-specific antigens, other means of selecting antigens
for epitope screening include identifying proteins that are
more common in virulent as compared to avirulent strains,
selection of genes differentially expressed in immunopathogenesis, prioritizing proteins exposed on the surface of the
pathogen and focusing on proteins that are expressed early in
the course of natural infection. The Expert Protein Analysis
System (ExPASy) proteomics server of the Swiss Institute of
Bioinformatics offers a wide variety of proteomics tools that
can be used for this purpose, including tools related to protein identification and characterization. Our groups have
adapted an approach first described by Gennaro et al. for
Mycobacterium tuberculosis (Mtb) [49], employing a series of
ExPASy tools (SignalP, TMPred and Prosite Scan [50]) to triage pathogen genomes, reducing the number of potential targets from thousands of proteins to several dozen candidate
antigens. In our first test of this approach, we found that a
subset of epitopes derived from the Mtb genome elicited
IFN-g response from Mtb-exposed human samples, and prototype epitope-based TB vaccines were shown to be robustly
immunogenic in murine studies [51].
Immunogenicity scale: ranking antigens

Once a set of antigens is selected using the methods described
above, tools available through the iVAX toolkit can be used to
rank proteins for relative immunogenicity, based on their putative T-cell epitope content. For this purpose, iVAX calculates
an ‘immunogenicity score,’ which represents the deviation
between the number of putative epitopes found in a given protein and the number we would expect to find in a randomly
generated protein sequence, taking care to adjust for protein
size. In this context, an immunogenicity score of zero reflects
random or ‘average’ putative epitope content; positive scores
25
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Figure 1. Lymphatic filariasis antigens on the EpiMatrix
protein immunogenicity scale. All other factors being equal,
the more HLA ligands (i.e., putative T-cell epitopes) contained in
a given protein, the more likely that protein is to induce an
immune response. To capture this concept, the EpiMatrix immunogenicity scale presents proteins by the EpiMatrix protein score,
and compares them to other known immunogens. The EpiMatrix
protein score is the difference between the number of predicted
T-cell epitopes expected in a protein of a given size and the
number of putative epitopes predicted by the EpiMatrix. The
EpiMatrix protein scores are ‘normalized’ and can be plotted on
a standardized scale. ‘Average’ proteins score near zero. Protein
scores above zero indicate the presence of excess MHC ligands
and denote a higher potential for immunogenicity, while scores
below zero indicate the presence of fewer potential MHC ligands
than expected and a lower potential for immunogenicity. The
EpiMatrix protein score is correlated with observed immunogenicity in vitro and in vivo. As shown here, proteins scoring above
+20, such as Brugia malayi antigen Juv-p120, are considered to
have a significant immunogenic potential. Proteins scoring
below –20, such as TPX-2 above, are less likely to be immunogenic in vivo.

reflect more epitope content than expected, while negative
scores reflect less epitope content than expected [52]. Large
numbers of protein sequences derived directly from the genome
of selected pathogens can be ordered by potential class I
(CTL), class II (T helper) or both class I and class II epitope
content and placed on an immunogenicity scale (FIGURE 1).
This tool allows researchers to quickly rank a given set of proteins both in relative (i.e., relative to each other) and absolute
(i.e., relative to a panel of known immunogens and nonimmunogenic proteins) terms [53]. In our experience, epitope-rich
proteins are good vaccine targets and elicit strong antibody
26

responses – thus, as previously stated, T-cell epitope content is
a useful proxy for overall immunogenic potential.
Antigen selection is particularly complicated when targeting
parasitic organisms due to their comparatively massive genomes
and multistaged life cycles, and ranking of these antigens may
assist with the selection of better targets. For example, in FIGURE 1,
we show two candidate antigens derived from B. malayi, a causative agent of lymphatic filariasis, whose life cycle is divided into
multiple larval stages including a microfilarial stage [54]. In this
case, TPX-2, a protein that has been identified as a potential vaccine target [55], is shown to contain minimal T-cell epitope content, with an immunogenicity score of –27.61, and thus it may
be less successful as a vaccine candidate. In contrast, Juv-p120, a
B. malayi ortholog of a Litomosoides sigmodontis antigen implicated in conferring protection against microfilarial infection [56]
carries substantially more T-cell epitope content, scoring
+94.14 on the immunogenicity scale, in the same range as other
well-known immunogens. Furthermore, as is illustrated here in
the case of B. malayi, we frequently find evidence that pathogens
appear to reduce T-cell epitope content in key proteins to avoid
human immune responses. Epitope deletion is an established
means of immune evasion in HIV and HCV [57,58]; thus, the
mechanism may also be relevant in the context of infections that
are associated with chronic infection caused by filaria, leishmania
and other chronic NTD, particularly in stages associated with
chronic parasitism and parasite persistence in the face of immune
pressure. We will discuss additional means of immune evasion
that can be uncovered by computational tools below.
EpiMatrix: T-cell epitope mapping of selected antigens

T-cell epitopes are short linear peptides that can bind to MHC
molecules and engage T cells through their receptors (TCR),
activating specific populations of CD8+ and/or CD4+ lymphocytes. These epitopes are key to forming the immunological
synapse between antigen-presenting cells and T cells. Because
TCRs are produced in a myriad of possible conformations
(much like antibodies, to which they are related), MHC binding is the dominant event in immune recognition. In other
words, most MHC ligands are also T-cell epitopes, and T-cell
epitopes are by definition, MHC ligands. The MHC-peptide
interaction is well characterized [59,60]. Based on these characterizations, pattern-matching algorithms such as EpiMatrix have
been developed to screen protein sequences for peptides that
will bind MHC.
The human MHC molecules, or HLA, are among the most
variable proteins in the human genome. This variation ensures
that the surveillance capabilities of the human immune system
are both broad and deeply redundant, making immune escape
through mutation more difficult for pathogenic organisms. Fortunately, some alleles are much more common than others in
the human population and the binding repertoire of many
alleles significantly overlap.
By focusing on alleles that are both common (in the human
population) and significantly different from each other (representative of human diversity), HLA alleles can be grouped into
Expert Rev. Vaccines 14(1), (2015)
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‘supertypes,’ which can reduce the search space to a manageable
number of evaluations. Six of these class I super-type alleles
that ‘cover’ the genetic backgrounds of most humans worldwide have been used to define CTL epitopes: A*0101, A*0201,
A*0301, A*2402, B*0702 and B*4403 [61]. For class II
T helper epitopes, mapping for a panel of eight common
alleles: DRB1*0101, *0301, *0401, *0701, *0801, *1101,
*1301 and *1501, gives broad T helper epitope coverage [62].
The concept of supertype alleles is generally accepted and
widely applied to vaccine design in the field of computational
vaccinology [61,62].
Using the set of selected protein antigens as a starting point,
iVAX uses EpiMatrix to parse each into overlapping 9-mer
frames where each 9-mer overlaps the last by eight amino acids.
Each 9-mer is then scored for predicted binding affinity to a
panel of class I or class II HLA alleles. The EpiMatrix algorithm compares the amino acid sequence of each given 9-mer
peptide to the coefficients contained in stored probability
matrices and produces a raw score. In order to compare potential epitopes across multiple HLA alleles, EpiMatrix raw scores
are converted to a normalized ‘Z’ scale. Peptides scoring above
1.64 on the EpiMatrix ‘Z’ scale (typically the top 5% of any
given sample) are likely to be MHC ligands [63]. Evidence from
animal studies suggests that the number of epitopes required
for full protection is a small and definable subset (~50) [64,65];
thus, epitope-driven vaccines developed by our group generally
contain a payload of 50–100 epitopes that provide broad coverage of human genetic backgrounds. With a combination of
promiscuous class II epitopes and class I supertype epitopes, it
is possible to attain >99% coverage of the HLA of most human
populations [61,62].
Eliminating regulatory or suppressor epitopes using
JanusMatrix

A recent development in vaccine design includes the consideration of epitopes that induce regulatory or suppressive immune
responses [66]. Our group has been investigating epitope crossconservation with the human genome and its association with
diminished or regulatory immune responses. Using a recently
developed tool called JanusMatrix we first determined that
published effector T-cell epitopes can be distinguished from
reported regulatory T-cell epitopes on the basis of TCR-specific
cross-reactive potential with the human genome and human
microbiome [67]. JanusMatrix differs from whole-sequence
alignment tools such as BLAST [68] in its basis upon T-cell
receptor homology. Pathogenic peptides whose TCR-facing residues are identical to the epitopes contained in multiple self
may be recognized by T cells specific to those human proteins.
Of course, even though the MHC-facing residues may differ,
these peptides must still have the capacity to bind to the same
MHC as the pathogen sequence, provided that binding is preserved. Taking this into account, JanusMatrix compares the
TCR-facing contour of pathogen ligands to other genomes of
interest, identifying matches therein that are predicted to bind
the same MHC. TCR-homologous epitopes shared between
informahealthcare.com
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pathogens and humans, or pathogens and other microbes, can
be uncovered with remarkable speed using the JanusMatrix
tool.
Exploring further, we have uncovered a high degree of host
(human) homology in viruses that tend to establish chronic
infections in humans such as EBV and CMV [69]. Furthermore,
‘commensal’ viruses can be shown to contain significantly more
human genome-homologous epitopes relative to those causing
acute infection (e.g., Ebola, Marburg) [69]. The limited clinical
efficacy of some vaccines against selected microbial pathogens
may, in fact, have been due to their extensive crossconservation with the human genome [10]. The JanusMatrix
tool is currently being used by our team and collaborators to
identify significant homology between candidate payload epitopes and proteins contained within the human genome and the
human microbiome. Using the tool, we find that not only
viruses but also bacteria that establish chronic infections in
humans ‘deimmunize’ (remove T-cell epitopes) and ‘tolerize’
(modify epitopes to be more cross-reactive to human T-cell
epitopes). Comprehensive studies of NTD genomes (and stageby-stage analysis of parasite antigens) will be performed using
the JanusMatrix tool in the near future.
It follows that careful selection of T-cell epitopes, and redesign of whole antigens, to avoid the inclusion of T-cell epitopes
that may be highly cross-reactive with the human genome
could improve the efficacy of whole-antigen and epitope-based
vaccines. JanusMatrix complements recent research [70] on the
development of adaptive immunity and supports the hypothesis
that adaptive T-cell responses are reinforced by cross-reactivity
with the human microbiome [71–73].
Cytoscape is an online tool that is usually used by bioinformaticians to illustrate the relatedness between proteins, for
example, all of the intracellular proteins that might be involved
in the stimulation of a cell through toll-like receptors. We have
repurposed Cytoscape to describe the relationship between epitopes across proteins in groups of sequences (the human
genome, the human microbiome, pathogen genomes [67]).
Using Cytoscape [74], the results of JanusMatrix analysis (e.g.,
comparing a pathogen epitope to the human genome) can be
visualized as networks where each epitope derived from a pathogen is linked to its TCR-matched counterparts in the search
database, which themselves are linked to their source proteins.
For example, an influenza T-cell epitope previously identified
by Mark Davis and colleagues [70] that stimulates T cells in
subjects never exposed to influenza can be shown to have an
extensive network of cross-reactive TCR-facing epitopes in the
human microbiome. In contrast, an epitope from vaccinia virus
synthesized and tested by Larry Stern’s group is shown to have
extensive cross-reactivity with the human genome by JanusMatrix. This epitope was nonimmunogenic in vitro (by IFN-g
ELISpot) even though it was shown to bind to the correct class
II MHC [75]. This epitope fits the emerging in silico definition
of a Treg epitope.
Due to their commensal nature and need to avoid human
immune responses over many years of coexistence, it is even
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A

type of analysis for the selection of candidate epitopes for NTD.

B

ClustiMer: finding promiscuous T-cell
epitopes

Potential LF Treg epitope
(TPX-2)

C

Potential LF Teff epitope
(Juv-p120)

D

Published Treg epitope
human IgG

Potential Teff epitope
CEFT pool

Figure 2. JanusMatrix analysis. This tool considers identity of TCR-facing residues to
target proteins or genomes independently from residues that contribute to MHC
binding. Peptides that have similar TCR-facing residues and are presented in the context
of the same HLA can be identified. Extensive homology is easy to identify using the
Cytoscape network visualization tool. The extent of the network can be used to
distinguish potential regulatory T-cell epitopes (A) from potential effector T-cell epitopes
(B). A published Treg epitope example is shown in (C), and several published Teff
epitope examples are shown in (D). For these illustrations, yellow hexagons identify the
source antigens, turquoise diamonds identify the source T-cell epitope clusters, gray
squares indicate the source 9-mers, dark blue triangles indicate matched human 9-mers
and light blue circles indicate human antigens in which matched 9-mers are found.
Data for C, D taken from [67].

Promiscuous HLA binding potential is a
feature of class II-restricted T-cell epitopes particularly exploitable for vaccine
design purposes. It has been shown that
putative epitopes for HLA class II are not
often distributed evenly across protein
sequences, but instead tend to cluster in
specific regions, where it is not uncommon to observe several reactive 9-mer
frames in close proximity [76]. These
‘clusters’ of unusually high predicted epitope density can be identified in silico
using the ClustiMer algorithm. In general, T-cell epitope clusters identified by
the ClustiMer algorithm tend to be promiscuous MHC binders and are frequently T-cell epitopes [52]. Due to
overlapping peptide-binding preferences
among HLA-DR alleles, it is also possible
to identify single 9-mers capable of binding four or more HLA alleles [76]. These
sequences have been dubbed ‘EpiBars’
due to their horizontal, band-like signature in readout from EpiMatrix (FIGURE 3).
T-cell epitope clusters can be very powerful, and EpiBars may be a characteristic
feature of highly immunogenic, promiscuous class II epitopes. These compact,
highly reactive peptides are relatively easy
to deliver and show great promise as vaccine components when cross-reactivity
with the human genome is limited (see
above). We have used these clusters
extensively in our own work [24,43,51].
Class I epitope selection

more likely for selected human parasites to share putative T-cell
epitope content with their human hosts. In FIGURE 2, we offer two
example peptides from B. malayi antigens TPX-2 and Juv-p120,
compared to published Treg epitopes from human immunoglobulin (Tregitopes) and effector epitopes, the CEFT pool (a
set of peptides used as ‘control positive’ peptides in ELISpots [67]). The potential cross-reactivity network differential is
evident between the TPX-2 epitope, with many related epitopes
derived from human sequences, and the Juv-p120 sequence,
whose related human epitopes are few. This finding underscores
the importance of validating the response phenotype of T cells
stimulated by epitopes identified in silico prior to their inclusion
in vaccine constructs, and also illustrates the importance of this
28

Promiscuous T-cell epitopes also exist, to
a certain degree, for class I alleles; however, this is much less
common than for class II. Some laboratories have demonstrated
cross-presentation of peptides within HLA ‘superfamilies,’ such
as the A3 superfamily: A3, A11, A31, A33 and A68 [77]. CrossMHC binding and presentation to T cells has been confirmed
in HIV vaccine studies [78]. However, we have found that
weighting toward the selection of highly promiscuous class I
epitopes may lead to identification of candidate epitopes that
have lower binding affinities overall. Higher binding affinities
appear to be a critical aspect of CTL epitope efficacy [79], thus
our group prefers to select a small set of the best-scoring putative epitopes for each of the six class I HLA superfamilies from
a given protein or set of conserved peptides (FIGURE 4).
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EpiMatrix cluster detail report
Representative T cell epitope cluster: Brugia malayi Juv-p120
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–0.15
0.06
2.1
0.95
0.65
–0.37

1.23
0.74
0.57
2.14
–0.58
0.78
0.36

0
0
1
8
0
0
0
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EpiMatrix score: 13.55

2
2.1
2.14
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1
9
EpiMatrix score (w/o flanks): 16.81

Figure 3. Example of an EpiBar: EpiMatrix analysis of candidate lymphatic filariasis epitope. In addition to providing an overall
immunogenicity score, EpiMatrix can be used to analyze epitopes at the local level. A Brugia malayi Juv-p120 peptide is shown above,
parsed into 9-mer frames and analyzed for predicted immunogenicity. EpiMatrix assessments above 1.64 constitute the top 5% of predicted HLA binders and are shaded medium blue, while scores above 2.32 fall in the top 1% and are shaded dark blue. This Juv-p120
peptide registers significant scores for all eight alleles in EpiMatrix in a single 9-mer frame, and based on the EpiMatrix method, has a
cluster score of 16.81 (reflecting the number of predicted binders per amino acid length). Cluster scores higher than 10 are considered
to be significant based on retrospective and prospective studies carried out by the EpiVax group. The band-like pattern illustrated in
frame 35 is called an EpiBar and is characteristic of promiscuous epitopes.

EpiAssembler: generating immunogenic consensus
sequences

Selecting epitopes that are broadly reactive across circulating
strains can enhance broad applicability of new vaccines. The
problem of pathogen variability significantly complicates the
selection of epitopes for vaccine design. To address this problem, EpiVax has developed EpiAssembler [80] to identify sets of
overlapping, conserved and immunogenic epitopes and to
assemble them into extended immunogenic consensus sequences (ICS, FIGURE 5).
The theory behind developing ICS is that processing and
presentation of these sequences would allow for presentation of
the highly conserved class II-restricted epitopes contained in
the ICS in the context of more than one MHC. The resulting
peptide is not a ‘pseudo-sequence’ as such, since each constituent epitope occurs in its corresponding position in the native
protein; adjacent epitopes may be similarly conserved but not
in the same variant of the pathogen. The ICS approach has
been useful for identifying highly immunogenic epitopes for
HIV vaccine design [38]. Using HIV as an example, while the
full composite ICS peptides happen to be exactly conserved in
a few individual strains of HIV, each peptide represents a significant percentage of circulating strains because every constituent overlapping epitope is conserved in a large number (range
893–2254) of individual HIV-1 strains [38].
By extending the approach described above, it is possible to
develop completely synthetic antigens whose sequences are optimized for T helper potential. With an eye to structural considerations, even recombinant protein-only vaccines could be
optimized in this way, enabling primary cognate T help to be
maximized and B-cell memory to be elicited. An ideal vaccine
informahealthcare.com

might include whole proteins in addition to some epitopes;
some or all of these antigens could be optimized using the ICS
approach. Linking ICS epitopes to a carrier protein (such as a
surface protein target of B-cell response) would further maximize primary cognate T help, since B cells that capture the
recombinant proteins would be able to process and present
T helper epitopes derived from more variable proteins.
As compared with ICS, randomly selected counterparts, on
average, contain half as many binding motifs and cover
one-third fewer isolates [40]. To develop vaccines of equivalent
antigenic ‘payload’ using conventional methods would be
prohibitively expensive, as it would require use of multiple
variants of each antigen. We believe that this and
similar approaches that harness conserved T help have tremendous potential and deserves careful consideration in
vaccine design.
From genomes to vaccines: epitope annotation, validation
& down-selection

After generating a preliminary list of candidate vaccine
components, the next step in the iVAX approach is to review
the putative epitopes produced by the EpiMatrix system, adding qualitative and quantitative annotations wherever possible,
leading to an investigator-driven down-selection process. Putative epitopes derived from known antigens or from proteins
overexpressed during early stages of infection or proteins
known to be exposed to immune surveillance as reported in
the literature may be prioritized. Furthermore, putative epitopes
with the in silico profile of potential regulatory T-cell epitopes
(based on JanusMatrix analysis) are removed from further
consideration.
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Figure 4. Class I epitope ‘staircase’ ranking. In the process of generating a selection of predicted high-affinity class I epitopes for
inclusion in T-cell-driven vaccines, parsed 9-mers from any antigen are ranked by potential to bind supertype HLA alleles and collated in a
‘staircase’ report. In this example, the top five highest-scoring peptides from a given antigen are shown. In general, prioritizing class I
epitopes by score for each of the individual alleles is preferred to define epitopes that bind across alleles.

Individualized T-cell epitope measure

Algorithms can also be helpful to interpret vaccine component
responses in preclinical and clinical studies. In studies of
immune response to therapeutic proteins and vaccines, the
authors have observed that subject-to-subject variation in
T-cell response closely relates to subject HLA type and the
number of motifs or peptides that match the subject’s HLA
haplotype. To describe this relationship, EpiVax researchers
have developed a metric that may be useful in clinical
assessment of immune response to vaccines, called the
‘individualized T-cell epitope measure’ or iTEM. For a given
T-cell epitope, an individual’s iTEM score can be calculated
by weighting and summing the epitope’s EpiMatrix Z-scores
for each HLA allele in a given subject’s haplotype. This calculated score allows for individualized immunogenic potential to
be predicted based on the number of putative epitopes
30

contained in a protein and a given individual’s HLA haplotype. Using this score, it is possible to analyze the contribution of haplotype to the corresponding T-cell response. In
prospective and retrospective evaluations, significant correlations were found between the IFN-g response to a given antigen and the iTEM scores for individual subjects [42]. In
addition, correlations between the iTEM score and patient
HLA have been observed for antibody titers [40,81,82], reflecting
the importance of HLA-restricted T-cell responses to the genesis of a robust antidrug antibody response.
Iterative combinatorial analysis for vaccine design

A number of methods for enhancing epitope-based vaccines
have been described and implemented [83,84]. One approach is
to align the individual epitopes in a protein or DNA vaccine
construct as a ‘string of beads’ without any intervening
Expert Rev. Vaccines 14(1), (2015)
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sequences or spacers between the payload epitopes [85]. However, the lack of spacers between the payload epitopes has
raised concern that these sequences may contain junctional
epitopes. VaccineCAD, an algorithm that iteratively analyzes
epitope assemblies and minimizes the potential for junctional
immunogenicity in any string-of-beads construct, has been
developed to address this concern [40]. Peptide sequences contained in the junctional regions between the target epitopes are
evaluated for potential immunogenicity. The highest scoring
junction is identified and the algorithm optimizes the order of
epitopes by evaluating potential alternative sequences. The process is repeated until no additional reductions in junctional
immunogenicity can be achieved or until all junctional immunogenic potential has been eliminated. When the potential for
junctional immunogenicity cannot be sufficiently reduced, a
cleavage promoting spacer sequence, typically ‘AAY’ for class I
restricted constructs [86] or a binding inhibiting ‘breaker’
sequence such as ‘GPGPG’ for class II restricted constructs [87]
is placed between the two offending epitopes. The ability to
minimize junctional immunogenicity while simultaneously
minimizing the presence of transmembrane domains or highly
hydrophobic peptide segments which may be difficult to
express would be a logical extension of this tool’s capabilities.
Successful vaccine design

The integration of computational tools for epitope discovery
has enabled the development of genome-derived vaccines [41,45,44]. Compared to conventional strategies, this
approach has the potential to create more effective and safer
next-generation vaccines, as carefully selected epitopes focus
immune responses on the minimal, essential pathogen-specific
antigenic elements; epitopes directed against conserved ‘self’
(host) antigens are eliminated. This approach is also well suited
for highly variable pathogens, as selection of epitopes that are
conserved across multiple strains or subtypes enables the development of a broadly applicable, multipathogen vaccine. The
genome-derived vaccine strategy has been applied by our team
to a wide range of pathogens, including F. tularensis, variola,
HIV, Mtb, H. pylori and influenza. These studies demonstrate
that immunoinformatic-predicted epitopes are immunoreactive
in vaccinees and survivors of infection, and stimulate de novo,
protective immune responses in vivo in HLA transgenic mice
(e.g., [24–26,51]).
Epitope-driven vaccines offer distinct advantages over traditional subunit vaccines. Multiple epitopes derived from several
antigens can be packaged together. Thus, a broad-based
immune response directed against several different antigenic
proteins can be elicited without manufacturing and administering the entire protein, much of which will be immunologically
irrelevant. This may reduce formulation challenges, cost and
safety risk. The use of epitopes also mitigates safety concerns
arising from the use of intact recombinant proteins that may
have undesired biological activity.
This review of vaccine design tools developed by the EpiVax
team is by no means comprehensive, and has mainly focused
informahealthcare.com
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Figure 5. EpiAssembler construction of immunogenic
consensus sequences. This figure illustrates the process of
assembling highly conserved T-cell epitopes into a single
molecule. First, a highly conserved, promiscuous epitope is
identified to form the 9-mer core of the ICS peptide (red bar).
Overlapping conserved epitopes (pink, orange, green and blue
bars) are then added to the N- and C-termini of the peptide until
a suitable length is reached for binding in the class II HLA
binding groove. This economical approach allows for targeting of
multiple strains of a given pathogen using a single peptide, as
illustrated by the blended bar at the bottom of the figure.
ICS: Immunogenic consensus sequences.

on antigen selection and design. Topics not covered in this
review include formulation of epitope-driven vaccines, route of
delivery (mucosal, intradermal, etc.), adjuvanting, selection of
delivery vehicles and preclinical and clinical testing. A major
caveat concerning the use of the iVAX toolkit is that none of
the vaccines designed using these tools have advanced to the
clinic. Given the cycle of vaccine development, this is not surprising (it may take up to 20 years to develop a vaccine with
full industry support). Retrospective and prospective studies
have provided extensive validation of the tools described
here [10,28,46,47]. Nonetheless, algorithms developed and applied
by this group to a wide range of pathogens have met with significant preclinical success and are currently in use for the
development of vaccines against NTD parasites, EID viruses
and bioterror pathogens.
Access to nearly all of the tools described in this article is
freely available to trained users through the iVAX toolkit [88].
The website was developed with funding from the National
Institutes of Health in 2010. Access to the iVAX toolkit and
training on the tools is available for interested researchers under
collaborative agreements with the University of Rhode Island
(primarily for NTD, but other arrangements are possible).
Commercial users are directed to EpiVax [89], which provides a
secure-access version of the iVAX website for commercial users.
Expert commentary

In general, the field of vaccine research has been slow to adopt
new vaccine design tools, and even fewer NTD researchers are
familiar with the use of the tools, despite proof of principle for
the genome-derived vaccine approach and the fact that it significantly reduces time and effort to make vaccines. For EID,
‘tried and true’ approaches often win out over newer
31
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approaches, even though traditional approaches have no greater
likelihood of success. The MERS-CoV vaccine development
programs that have been implemented illustrate this principle;
despite the fact that the virus belongs to a family of coronaviruses that have a history of rapid evolution, vaccination
approaches are once again targeting the ‘spike’ protein.
A similar approach was used during the emergence of SARS
and completely failed to protect against rapidly evolving SARS
viruses in animal challenge models [9,90]. Application of
advanced immunoinformatics tools to NTD vaccines has also
lagged for a number of reasons. NTD researchers do not use
the tools because they lack access to and familiarity with them,
and there are no widely publicized examples focusing on diseases that impact the developing world.
A series of technical challenges for NTD vaccines have been
described recently, including antigen discovery, process development, preclinical development, clinical trials in resource-poor
settings and the immune response to NTD infection, including
what is commonly referred to as the IgE trap, through which
certain individuals, perhaps especially those in endemic regions,
may have elevated preexisting IgE antibodies for potential
NTD vaccine antigens, leading to increased risk with vaccination [91]. Computational vaccinology cannot currently address
all of these challenges; however, the approach described here
offers a unique opportunity to address certain hurdles early in
the developmental process. Early in the pipeline, antigen discovery using T-cell epitope prediction and ranking, along with
candidate epitope triage using cluster analysis and crossreactivity prediction provide valuable leads. Selected peptide
candidates can be screened ex vivo in order to verify the phenotype of the immune response prior to inclusion in a final
vaccine product.
Finally, T-cell epitope-based strategies are exceptionally platform-flexible, adaptable to synthetic peptide formulations deliverable in saline, emulsion or microparticle, or encoding into
plasmid vectors for DNA vaccination or recombinant protein
production, thus allowing for novel distribution strategies necessary to reach the world’s poorest. This flexibility extends to
the antigen discovery approach as well, in that many kinds of
targets may be explored using immunoinformatics tools.
A pertinent example for NTD and EID applies to vector-based
targets. Vaccine components based upon the salivary proteins
of arthropod vectors are already under investigation [92]. However, vector salivary antigens also have known immunomodulatory properties allowing for extended host tolerance [93,94]. The
same discovery and evaluation strategy described for pathogenic
antigens could be applied to such proteins, potentially providing a mechanism through which to stimulate robust immune

response in the absence of the immunomodulatory properties
of the complete salivary antigens.
Five-year view

The amount of data generated through new technologies, such
as next-generation sequencing, continues to expand exponentially. By applying these technologies to the study of EID and
NTD causative agents, and expanding our genomic knowledge
of these organisms, the feasibility of using high-throughput,
informatics-based tools for the identification of putative protein
and peptide targets increases. Vaccine efficacy may also
improve, as the selection of targets can be refined by comparing the antigen to other genome sequences, such as the human
genome and the human microbiome. The in silico-based
approach to vaccine design may also alleviate many of the
funding-associated challenges common to traditional vaccine
design, by reducing the number of assays that need to be performed to select vaccine targets. Reduced cost should allow for
the reallocation of critical funding to the testing of in silico-predicted targets and constructs. And finally, improved safety,
by eliminating human genome cross-conserved epitopes, may
reduce unwanted adverse effects. Looking further into the
future, we are confident that the evolution of the tools
described here will eventually contribute to the development of
personalized, on-demand vaccines [95].
Considering the importance of controlling infectious diseases
to global economic stability, the integration of computational
vaccinology tools and their application to the design of vaccines
for NTD and EID is of paramount importance. Delay is no
longer acceptable. Vaccine developers must implement computational vaccinology tools if they wish to contribute to improve
world health in the 21st century.
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Key issues
• New immunoinformatics tools have been developed that address critical problems in vaccine design.
• These tools have been extensively validated in preclinical models.
• The design of vaccines for neglected tropical diseases would benefit from expanded use of these tools.
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